CombiMatrix to Raise $6.8M in Private Placement to Keep Up With Rising Test Demand | GenomeWeb

By Justin Petrone

CombiMatrix said this week that it plans to sell almost $6.8 million of newly issued shares of its stock in order to help it meet growing demand for its molecular tests.

Net proceeds from the placement will be used to "fund growth initiatives and for general working capital purposes," the firm said in a statement. CEO Judd Jessup this week declined to discuss details until after the placement closes April 7.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.